Tumor necrosis factor-a (TNF), a major in¯ammatory cytokine, generates a wide variety of cellular responses via key cytoplasmic adaptor molecules named TNF receptor-associated factors (TRAFs). We report that TRAF2, TRAF5 and TRAF6 associate with apoptosis signal-regulating kinase 1 (ASK1), and a catalyticallyinactive ASK1 mutant blocks stress-activated protein kinase (SAPK)/Jun NH 2 -terminal kinase (JNK) activation by these TRAFs. A truncated derivative of TRAF2, which inhibits SAPK activation by TNF, blocks TNFinduced ASK1 activation. Furthermore, protection from TNF-induced cell death conferred by an ASK1 mutant is dependent upon TRAF2. Hence, ASK1 is a common mediator of TRAF-regulated SAPK and apoptosis signaling, and the TRAF2 ± ASK1 connection completes the signaling cascade from TNF to SAPK/JNK activation.
Introduction
Tumor necrosis factor-a (TNF) is a pleiotropic cytokine whose varied biological activities are signaled by triggering the aggregation of receptor monomers (Tartaglia and Goeddel, 1992) . These receptors, termed TNFR1 (p55) and TNFR2 (p75), are expressed in most cell types and are members of the growing TNF receptor superfamily, which includes the Fas antigen and CD40 (Smith et al., 1994; Nagata, 1997; Gruss, 1996; Naismith and Sprang, 1998) . Upon receptor aggregation, several cytoplasmic proteins, including TNFR1-associated death domain protein (TRADD) (Hsu et al., 1995 (Hsu et al., , 1996b , receptor-interacting protein (RIP) (Hsu et al., 1996a) , and TNF receptor-associated factor (TRAF) family members (Rothe et al., 1995) are then recruited to the intracellular domain of TNFR1 where they then form an active signaling complex.
To date, six members of the TRAF family have been found (Rothe et al., 1995; Cheng et al., 1995; Regnier et al., 1995; Cao et al., 1996; Ishida et al., 1996a,b; Arch et al., 1998) . All contain a conserved C-terminal TRAF domain that mediates homo-or heterooligomerization among the TRAF family and interactions with the cytoplasmic regions of the TNF superfamily (Rothe et al., 1995) . In addition to the TRAF domain, most TRAF proteins contain an Nterminal RING ®nger and several zinc ®nger structures that appear critical for their eector functions (Arch et al., 1998) . Apart from the signaling events initiated by the TNF receptor family members, TRAFs may also link other receptor-mediated signaling pathways. For example, TRAF6 is a component of interleukin-1 receptor (IL-1R) signaling complex, in which it induces the activation of nuclear factor-kB (NF-kB) and the stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) family following IL-1 binding (Cao et al., 1996) .
Although three of the known TRAF proteins (TRAF2, TRAF5 and TRAF6) are able to mediate the activation of SAPK (Song et al., 1997) , the molecular mechanisms coupling the TNFR signaling complex to SAPK have not been well characterized. However, considerable progress has been achieved in identifying the kinases immediately upstream to SAPK and the other members of the MAPK family (Kiefer et al., 1997; Kyriakis et al., 1994) . SAPK is phosphorylated and activated directly by the dual-speci®city MAPK kinases (MAPKKs), SEK1/MKK4 (Sanchez et al., 1994; Lin et al., 1995) and MKK7 (Tournier et al., 1997; Holland et al., 1997; Yao et al., 1997; Moriguchi et al., 1997) , which in turn are substrates of a group of highly divergent MAPK kinase kinases (MAPKKKs) (Kiefer et al., 1997) . A recently characterized MAPKKK, apoptosis signal-regulating kinase 1 (ASK1; also called MAPKKK5), can activate SEK1 and MKK7 (SAPK pathway), and MKK3 and MKK6 (p38 MAPK pathway) by direct phosphorylation (Ichijo et al., 1997; Wang et al., 1996) . ASK1 is responsive to TNF treatment in many cell types, and expression of dominant-negative ASK1 inhibits TNFinduced apoptosis in Jurkat and 293 cells (Ichijo et al., 1997) . In addition, ASK1 has been shown to be activated by reactive oxygen species (ROS) generation, and to be inhibited by the antioxidant, thioredoxin Gotoh and Cooper, 1998) . It remains to be determined how ASK1 is regulated by TNF signaling.
In the present study, we show that ASK1 associates with members of the TRAF family, and that these interactions require the conserved NH 2 -terminal zinc RING and TRAF-N motifs typical to TRAF family members. Activation of ASK1 by TNF can be blocked at the level of the TRAFs, while a catalytically inactive ASK1 mutant inhibits SAPK activation by TRAF2, TRAF5 and TRAF6. Interestingly, catalytically inactive ASK1 can only rescue cells from TNF-mediated apoptosis in the presence of endogenous TRAF2, as determined by comparing TRAF2-de®cient and wild-type control ®broblasts. Together, these data demonstrate a role for the TRAF2 ± ASK1 interaction in both SAPK activation and cell death signaling.
Results

ASK1 and TRAF proteins associate in vivo
To begin to assess whether TRAF2, TRAF5 and TRAF6 may regulate ASK1 we determined whether TRAFs and ASK1 could associate in a transfectionbased, co-immunoprecipitation assay. 293 and COS cells were transiently transfected with equal amounts of hemagglutinin (HA) epitope-tagged ASK1 and untagged TRAF2, and their interaction was determined by co-immunoprecipitation followed by Western blotting. We found that ASK1 associated with TRAF2 as demonstrated by the co-immunoprecipitation of HA-epitope-tagged ASK1 with anti-TRAF2 antibodies ( Figure 1a , left panel) and co-immunoprecipitation of TRAF2 with anti-HA ( Figure 1a , right panel). Western blots con®rming equal expression of TRAF2 or ASK1 are shown. Similarly, we also coexpressed HA-ASK1 with FLAG epitope-tagged TRAF5 or TRAF6 proteins and found association of ASK1 with these TRAFs (Figure 1b and c, respectively).
To con®rm that these interactions were speci®c, ASK1 and TRAF2 co-immunoprecipitations were repeated in embryonic ®broblasts (EFs) generated from TRAF2-de®cient or wild-type mice. Endogenously expressed TRAF2 was precipitated with anti-TRAF2 antibody and the immune complexes were subjected to immunoblotting with anti-HA antibody to detect the presence of transfected HA-ASK1. HA-ASK1 was only found in TRAF2 immunoprecipitates from wild-type EFs (Figure 1d 
Mapping of in vivo interaction domains between ASK1 and TRAF2
Sequence alignment of TRAF family members reveals several highly conserved regions which are known to mediate interactions with several targets . To de®ne the sites of interaction between ASK1 and TRAF2, we performed co-immunoprecipitations with wild-type ASK1 and TRAF2 mutant proteins cotransfected into 293 cells (Figure 2a) . Deletion of the entire C-terminal TRAF domain (TRAF2(1 ± 272)) resulted in a signi®cant reduction of ASK1 binding (Figure 2b , lane 6), while deletion of only the TRAF-C subdomain (TRAF2(1 ± 355)) had no adverse eect of TRAF2 association with ASK1 ( Figure 2b, lanes 4 and 5) . Hence, the TRAF-N domain, which is predicted to adopt a coiled-coil con®guration, appears to be essential for TRAF2-ASK1 interaction (Figure 2b , lane 6). However, neither the whole TRAF domain (TRAF2(272 ± 501)) nor the TRAF-N region (TRAF2(272 ± 358)) alone are capable of co-immunoprecipitating ASK1 (Figure 2b , lanes 8 and 9). Rather, the RING ®nger domain is also required for eective ASK1 binding, since in the absence of this region binding to ASK1 was strongly impeded in this assay (Figure 2b, lane 7) . Taken together, these results indicate that the TRAF-N and RING ®nger domains both contribute to ASK1 binding by TRAF2. ®broblasts generated from wild-type (lanes 1, 4 and 5) and TRAF2-de®cient (lanes 2 and 3) mice were transfected with HA-ASK1 (lanes 1, 3 and 5) or control vector (lanes 2 and 4). After 36 h, lysates were prepared and incubated with the indicated antibody (anti-HA monoclonal antibody or anti-TRAF2 polyclonal antibody). HA-ASK1 co-precipitating with endogenous TRAF2 was detected by immunoblot analysis using the anti-HA antibody. As a control for the presence of TRAF2, an equal amount of each immunoprecipitate was resolved by 12.5% SDS ± PAGE and immunoblotted with anti-TRAF2 (bottom panel)
TNF-dependent endogenous interaction between TRAF2 and ASK1
Given that the in vivo physical association between TRAF2 and ASK1 might simply result from their overexpression with a constitutive promoter, we tested whether this interaction occured under more physiological conditions. As a control, our anti-ASK1 antibody eectively immunoprecipitated HA-ASK1 (Figure 3a) . We then did a time-course of TNF-stimulation (200 ng/ml) and harvested the cells. Immunoprecipitation of proteins from cellular extracts with an anti-TRAF2 antibody, followed by immunoblotting with antibody against ASK1 demonstrated coprecipitation of these two proteins (Figure 3b ). The maximum interaction was observed at 15 ± 30 min of TNF treatment and decreased thereafter. As a control, ASK1 was not identi®ed following immunoprecipitation with an irrelevant antibody. Therefore, we can conclude that endogenous TRAF2 and ASK1 physically associate in a TNF-dependent manner.
TRAF activation of the SAPK pathway is mediated by ASK1
The ability of ASK1 to bind the three TRAF family members known to activate SAPK and NF-kB raised the possibility that ASK1 functions as a component of TRAF-mediated signaling events. In particular, the observed interaction of ASK1 with the SAPK-kinases SEK1 (Ichijo et al., 1997; Wang et al., 1996) and MKK7 (Z Yao, unpublished results) suggested that ASK1 might be a downstream event in TRAFmediated signal transduction. Consequently, we measured the eect of a kinase-de®cient ASK1 mutant, ASK1-K709E, on TRAF2-, TRAF5-and TRAF6-mediated SAPK and NF-kB activation. To examine whether ASK1 mediates SAPK activation by TRAFs, we co-transfected COS and 293 cells with mammalian expression plasmids encoding ASK1-K709E, HA-SAPK and TRAFs. Recombinant SAPK was immunoprecipitated from cell lysates and assayed with GSTc-Jun as substrate. Transfection of cells with ASK1 resulted in strong activation of SAPK (data not shown), con®rming previous observations (Ichijo et al., 1997; Wang et al., 1996) , whereas transfection of cells with vector alone or ASK1-K709E had no eect on SAPK activity (Figure 4a, lanes 1 and 2) . Cotransfection of ASK1-K709E along with TRAF2 and HA-SAPK into COS cells reduced SAPK activity 75% in the HA immunoprecipitates as compared with TRAF2 and HA-SAPK alone (Figure 4a, lanes 3 and  4) . Comparable results were obtained with TRAF5 and TRAF6 (Figure 4a , lanes 5 ± 8), although TRAF5-induced SAPK activation consistently was the least sensitive to the inhibition by ASK1-K709E. These results indicated that TRAF activation of the SAPK pathway might be mediated by direct eects on ASK1.
The inhibitory eect of ASK1-K709E on TNF-and TRAF-mediated NF-kB activation was investigated using a NF-kB-dependent reporter gene. In this experiment, overexpression of ASK1-K709E had no eect on E-selectin promoter-luciferase reporter gene activation by TNF, TRAF2, TRAF5 or TRAF6 (data not shown). This indicates that ASK1 is speci®cally required for TRAF-mediated SAPK activation.
TRAF2 regulates ASK1 activation by TNF
If ASK1 acts downstream of TRAFs, a dominant negative TRAF2 mutant should block TNF stimulation of ASK1 kinase activity. Therefore, we examined whether TRAF2 could modify the TNF-induction of kinase activity of transfected ASK1 cDNA. Immunoprecipitation of ASK1 followed by kinase assays demonstrated that TNF consistently increased ASK1 COS-7 cells were transiently co-transfected with HA-SAPK (5 mg; lanes 1 ± 8), expression vectors for ASK1-K709E (5 mg; lanes 2, 4, 6 and 8), TRAF2 (5 mg, lanes 4 and 5), TRAF5 (5 mg, lanes 5 and 6), TRAF6 (5 mg, lanes 7 and 8), or vector control to bring total DNA to 15 mg. Following immunoprecipitation with anti-HA antibodies, SAPK activity was assessed using GST-c-Jun(5 ± 89) as a substrate. TRAF2, TRAF5 and TRAF6 induce activation of SAPK (lanes 3, 5 and 7, respectively). However, in the presence of ASK1-K709E, SAPK levels are signi®cantly reduced (lanes 4, 6 and 8). As a control for SAPK or ASK1-K709E protein expression, an equal amount of each cell lysate was resolved by 12.5% or 6.5% SDS ± PAGE, respectively, and immunoblotted with anti-HA antibody. Similar results were obtained in atleast three independent experiments. (b) Dominant-negative TRAF2 can suppress ASK1 activation by TNF-a. Top panel: ASK1 phosphorylation of SEK1-KR. 293 cells were co-transfected with HA-ASK1 (lanes 2 ± 4), TRAF2(272 ± 501), a dominant-negative TRAF2 expression construct (lane 4), or control vector to bring total DNA for each transfection to 15 mg. Cells were stimulated with TNF-a as indicated. HA-tagged ASK1 proteins were immunoprecipitated with anti-HA antibody and then incubated in kinase buer with GST-SEK1-KR and ATP at 308C. Proteins were resolved by SDS ± PAGE, transferred to PVDF membrane by Western blotting, and immunoblotted with a polyclonal antibody raised to phosphorylated SEK1. In lane 1, no ASK1 was transfected to assess background activity. ASK1 activity increased signi®cantly upon addition of TNF-a (lanes 2 and 3). However, upon TRAF2(272 ± 501) co-transfection (lane 4), ASK1 levels were reduced to levels lower than its basal activity. The relative expression levels of HA-ASK1 were measured by immunoblotting of whole-cell extracts from transfected cells with anti-HA antibody. Bottom panel: Inhibition of ASK1 by TRAF2(272 ± 501) in MBP kinase assay. 293 cells were transfected as described in the top panel. Immunoprecipitated HA-ASK1 kinase activity was measured by MBP as a direct substrate for ASK1. ASK1 activity was then determined by Phosphoimage analysis. ASK1 activity was elevated by TNF-a (lane 3), but was attenuated upon co-transfection of dominantnegative TRAF2 (lane 4) Figure 5 Mechanism of cell death inhibition by ASK1. The indicated cells lines were transiently co-transfected with 0.5 mg pCMV-bgal and 2.5 mg of ASK1-K709E or control vector as indicated. After transfection (24 h), 10 ng/ml TNFa and 250 ng/ ml cycloheximide (®nal concentrations) were added for 24 h. Subsequently, cells were ®xed and stained with X-Gal. Data (mean+s.e.m.) is plotted as the number of blue cells per well (as a percentage of the unstimulated control) for at least three independent transfections phosphorylation of SEK1 and myelin basic protein (MBP) approximately twofold in each case (Figure 4b and c, lane 3). By comparison, in the presence of TRAF2(272 ± 501), a deletion mutant known to be defective in activating SAPK, ASK1 kinase activity in response to TNF was signi®cantly reduced (approximately sixfold, Figure 4b and c, lane 4). Western blot analysis of extracts used in Figure 4b and c showed similar expression of ASK1. The ®nding that a TRAF2 mutant can block ASK1 activation by TNF is consistent with the positioning of ASK1 downstream to TRAF2 in TNF signaling.
Overexpression of dominant-negative ASK1 inhibits TNF-mediated apoptosis only in the presence of TRAF2
To further study the functional role of the ASK1 ± TRAF2 interaction, wild-type and TRAF2-de®cient mouse embryonic ®broblasts (EFs) were transfected with pairs of expression plasmids encoding b-gal and either ASK1-K709E or control vector at a 1 : 5 ratio, respectively (Yeh et al., 1997) . Twenty-four hours later, cells were treated with murine TNF-a (10 ng/ml) and cycloheximide (0.25 mg/ml) for a subsequent 30 h. Under these conditions, TRAF2-de®cient cells begin to die as early as 6 h after treatment and less than 5% of the mutant cells survive by 30 h after treatment. Similar treatment has a less adverse eect upon wildtype EFs and approximately 20% survival is generally seen after 30 h. Following treatment, cells were stained with X-Gal and morphologically normal, positive blue cells were visualized and counted. A quantitative representation of the data from three independent transfections is shown in Figure 5 . In wild-type, but not traf2
, ®broblasts a threefold increase in the viability of b-galactosidase-positive cells was observed following expression of ASK1-K709E compared with the control vector (Bonferroni t-test, P50.05). The wild-type EFs transfected with ASK1-K709E were also signi®cantly protected from the accompanying morphological alterations of apoptosis (data not shown). In contrast, TNF-treated wild-type EFs expressing control vector displayed morphological alterations typical of adherent cells undergoing apoptosis, becoming rounded, condensed, and detaching from the dish (data not shown). Taken together, this data suggests that ASK1-K709E overexpression eectively blocks a TRAF2-dependent, TNF-induced apoptosis cascade. Hence, in addition to the cell survival pathways mediated by TRAF2, its interaction with ASK1 can also likely lead to programmed cell death.
Discussion
The TNF receptor-associated factor (TRAF) family of adaptor proteins mediate signals from cell surface receptors to various protein kinase cascades, including the stress-activated protein kinase (SAPK) pathway (Arch et al., 1998) . Since TNF-induced SAPK activation is defective in TRAF2-de®cient cells (Yeh et al., 1997 ), TRAF2 appears to regulate SAPK activation at a very proximal step. The data presented here suggest that TRAF2 transduces signals for SAPK activation via the MAPKKK ASK1. During preparation of this manuscript, similar ®ndings were reported by Nishito et al. (1998) . Our analysis of the association of TRAF2 with ASK1 is consistent with the current model of TNF signaling, wherein bifurcation of the TNF-induced NF-kB and SAPK activation pathways occurs at the level of TRAF2 (Song et al., 1997) . Comparable to the role of ASK1 in SAPK activation, another MAPKKK homolog, NF-kB-inducing kinase (NIK), has recently been identi®ed as a TRAF2-interacting protein and a common downstream mediator of NF-kB activation by TNF and TRAFs (Malinin et al., 1997; Natoli et al., 1997) . Overexpression of NIK appears to be speci®c for NF-kB induction and has no eect on SAPK activity (Natoli et al., 1997; Song et al., 1997) . By comparison, TRAF2, TRAF5 and TRAF6 also activate ASK1, which in turn activates the SAPK pathway, but not NF-kB. Collectively, these results further demonstrate that despite several common mediators, SAPK and NF-kB activation by TNF are two separate responses.
TNF is also known to upregulate a third MAPKKK, MAPK/ERK kinase kinase 1 (MEKK1), another activator of the SAPK pathway (Yan et al., 1994) . It has been proposed that the carboxy-terminal regulatory domain of germinal centre kinase (GCK), can bind both TRAF2 and MEKK1, thereby constituting an ASK1-independent signaling pathway from TRAF2 to SAPK (Pombo et al., 1995; Yuasa et al., 1998) . However, the physiological eect of this interaction is likely to dier somewhat from that of TRAF2-mediated ASK1 activation. For instance, while we show that in addition to impeding SAPK activation, a dominant-negative ASK1 mutant also blocks TNF-induced apoptosis in the presence of TRAF2 (Figure 5 ), no apoptosis function has been yet assigned to GCK. Also, through TRAF2's interaction with the cytoplasmic death domain-containing proteins TRADD and RIP (Hsu et al., 1995) , ASK1-mediated apoptosis likely precedes caspase activation. When analysed for cleavage by caspases during programmed cell death, ASK1 was unaected (KP Hoo¯ich and JR Woodgett, unpublished data). In contrast, MEKK1 is activated by caspase-cleavage (Cardone et al., 1997; Widmann et al., 1998) and is thus predicted to be involved in apoptosis-induced SAPK signaling downstream of caspase activation during the degradation phase of apoptosis (Frisch et al., 1996; Park et al., 1996) . Recent data has also implicated MEKK1 as having a role in the activation of IkB-kinase (IKK), a component in the antiapoptotic, NF-kB activation pathway (Karin and Delhase, 1998) .
Eorts to elucidate the mechanisms of MAPKKK regulation have been hampered by the fact that all mammalian SAPK-activating MAPKKKs identi®ed thus far are constitutively active upon overexpression. Correspondingly, while ASK1 can associate with components of the TNFR1 complex, mere overexpression of ASK1 results in its potent activation, overwhelming any endogenous inhibitors present in limiting concentrations. Since ASK1 interacts predominantly with the TRAF-N domain of TRAF2 (Figure 3b ), one such class of inhibitors could be the IAPs (inhibitor of apoptosis proteins) which also bind the same TRAF2 domain (LaCasse et al., 1998; Rothe et al., 1995) . We can hypothesize that the pro-apoptotic ASK1 and antiapoptotic IAPs could compete for TRAF2 binding.
However, upon testing, no evidence was found for mutually exclusive binding of ASK1 and HIAP1/ HIAP2 to TRAF2 (KP Hoe¯ich and JR Woodgett, unpublished data). In addition, ASK1 has recently been shown to interact with the Fas receptor-associated protein, Daxx (Chang et al., 1998) . Hence, future work in evaluating the role of ASK1 in TNF-or Fasmediated apoptosis will be aided by the targeted disruption of ASK1 in mice.
Materials and methods
cDNA constructs
Hemagglutinin (HA) epitope-tagged expression plasmids for ASK1/MAPKKK5, catalytically inactive ASK1-K709E (Wang et al., 1996) , p54-b-SAPK (Pulverer et al., 1991) , kinase-inactive SEK1-KR (Yan et al., 1994) , and FLAG epitope-tagged TRAF5 (Song et al., 1997) have been previously described. TRAF2 and TRAF6 cDNAs were isolated by reverse transcription-PCR, and the full-length coding regions were cloned into the eukaryotic expression vector pCR3.1 (Invitrogen), and in the process were fused to an N-terminal FLAG epitope tag (SIGMA). Expression vectors for TRAF2 deletion mutants were constructed by PCR ampli®cation of TRAF2 coding sequences using oligonucleotide pairs as shown, and ligating the resulting fragments into pCR3.1: for TRAF2(98 ± 501), primers 69 (5'-CTACCATGGACTA CAAGGAC GACGATGACAAGAG-GGAGGTGGAGAGCCTG-3') and 54 (5'-TTAGAGCCCT-GTCAGGTC-3'); for TRAF2(272 ± 501), primers 63 (5'-CTACCATGGACT ACAAGG ACGACGAT GACAAGTG-CGAGAGCCTGGAGAAG-3') and 54; for TRAF2(1 ± 271), primers 48 (5'-CTACCATGGACTACAAGGACGACGAT-GACAAGATGGCTGCAGCTAGCGTC-3') and 59 (5'-TTACCTCTGCAGGAGCTCTGA-3'); for TRAF2(1 ± 355), primers 48 and 64 (5'-TTAGATGAAGACCCCATCGTAG-3'); for TRAF2(272 ± 358), primers 65Rev (5'-CTACCATG-GACTACAAG GACGACGATGACA AGTCAGA GCTCC-TGCAGAGG-3') and 66Rev (5'-GAAAGTCTGAGATCT-TCCA-3'); and for TRAF2(1 ± 436), primers 48 and 88 (5'-TTAGTCGAGCAGCATTAAGGTC-3'). GST-c-Jun(5 ± 89) fusion proteins were produced in the pLysS(BL21DE3) strain of E. coli using the pGEX expression system (Promega). Proteins were anity puri®ed on glutathioneagarose beads and eluted with 10 mM reduced glutathione, 50 mM Tris pH 8. Eluted proteins were dialysed against a buer containing 50 mM Tris pH 8, 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 0.1% 2-mercaptoethanol, and 50% glycerol. Restriction enzymes, ligase and polymerase were obtained from New England Biolabs or as indicated. Oligonucleotides were purchased from GIBCO.
Cell culture, transfection and treatment 293, COS-7 and mouse embryonic ®broblast cells were maintained in Dulbecco's modi®ed Eagle's media supplemented with 10% fetal calf serum. Cells were plated at a density of 2610 6 cells/100-mm dish and transfected the next day using the calcium phosphate transfection protocol. The amounts of DNA used for transfection were as indicated, and the empty vectors were used to achieve equal amounts of DNA in each transfection. Where added, recombinant human TNF-a(Genetech) was used at a ®nal concentration of 100 ng/ml (30 min prior to lysis). Cell lysis was performed in Gentle-Soft lysis buer with inhibitors (1 mM dithiothreitol, 100 mM sodium orthovanadate, 5 mg/ml leupeptin, 50 mM sodium¯uoride, and 1 mM benzamidine) at 48C. Lysates were cleared by centrifugation at 13 000 g for 10 min, and then normalized for total protein by Bradford assay before immunoprecipitation.
Immunoprecipitations and immunoblotting
Immunoprecipitations were performed using monoclonal antibody against the HA tag generated from culture supernatants of 12CA5 hybridoma (ATCC), monoclonal antibody against the FLAG epitope (Kodak), polyclonal rabbit antibody raised against murine TRAF2 (UBI), or polyclonal ASK1 antibody (Santa Cruz Biotechnology). Epitope-tagged proteins were immunoprecipitated by incubating the appropriate cell lysates with 20 ml anti-HA or 0.2 mg anti-FLAG antibodies for 1 h and harvested with 10 ml of protein G-Sepharose (Pharmacia). Endogenous TRAF2 was precipitated by incubation with 1 mg TRAF2 antibody and harvested on protein A-Sepharose beads. The immune complexes were washed four times in PBST (150 mM NaCl, 16 mM Na 2 HPO 4 4 mM NaH 2 PO 4 , 0.1% Triton X-100, 1 mM dithiothreitol, 100 mM sodium orthovanadate, 5 mg/ml leupeptin, 50 mM sodium¯uoride, and 1 mM benzamidine). For analysis of protein-protein interactions, immune complexes were resolved by SDS ± PAGE and immunoblotted with the indicated antibodies. A polyclonal rabbit antibody raised to phosphorylated threonine 223 of human SEK1/ MKK4 (New England Biolabs) was used to detect phosphorylated SEK1 proteins.
Kinase assay
To assay SAPK and ASK1 activity, an equal volume of protein normalized HA-SAPK or HA-ASK1 cell lysates, respectively, were incubated with 20 ml anti-HA antibodies for 1.5 h and harvested with 10 ml of protein G-Sepharose (Pharmacia). After four washes with PBST, the beads were incubated with glutathione S-transferase (GST)-c-Jun(5 ± 89) (SAPK substrate), GST-SEK1-KR (ASK1 substrate) or myelin basic protein (ASK1 substrate), 40 mM ATP, 10 mM MgCl 2 , 50 mM Tris-HCl pH 7.5, 1 mM EGTA, and 40 mCi/ mL [g-32 P]ATP at 308C (Adler et al., 1992) . After 20 min, the reactions were terminated by addition of Laemmli sample buer. Samples were boiled, and phosphorylated proteins were resolved on sodium dodecyl sulfate-12.5% polyacrylamide gels and visualized by PhosphoImager analysis (Molecular Dynamics).
Embryonic ®broblast death assay
EF cells were grown in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal calf serum. Cells were transfected at 50% con¯uency in 6-well dishes with 0.5 mg of pCMV-b-galactosidase plus 2.5 mg of empty control vector or pCDNA3-ASK1-K709E. After 24 h, recombinant mouse TNF-a (Gibco BRL) was used at 10 ng/ml, and cycloheximide (Sigma) was used at 250 ng/ml for 24 h. bGalactosidase cotransfection assays were performed as previously described (Kumar et al., 1994) , and cells were visualized by phase-contrast microscopy, and the number of blue cells per well determined by counting.
